Lee Jieun, Kim Yu-Mi, Yoo Seungwon, Kim Dae-Young, Shin Sung-Hee, Na Jin Oh, Shin Jinho, Park Kiho, Lee Eun Mi
Division of Cardiology, Department of Internal Medicine, Korea University Guro Hospital, Seoul, Republic of Korea.
Department of Preventive Medicine, Hanyang University College of Medicine, Seoul, Republic of Korea.
Hypertens Res. 2025 Sep 3. doi: 10.1038/s41440-025-02364-z.
The implementation of Home Blood Pressure Monitoring (HBPM) has improved the diagnosis and treatment of hypertension. Current clinical guidelines advocate the use of validated HBPM devices. However, few studies have examined the current use of validated HBPM devices. We aimed to investigate the current status of the use of validated HBPM devices in real-world hypertensive patients. This study was conducted on Korean patients with hypertension using CareforMe®, a smartphone healthcare application which allows the patients to record their HBPM data which can be shared with their physicians. The validation status of HBPM devices was identified based on four registries: STRIDE BP, Medaval, the Japanese Society of Hypertension, and dabl® Educational Trust. From January 2022 through August 2024, 2731 patients entered the model numbers of their HBPM devices. 56.4% (n = 1539) of the population were male, and the mean age was 53.5 ± 10.8 years old. 110 models from 33 different manufacturers were identified. 97.0% (n = 2649) of the patients used upper-arm devices and 3.0% (n = 82) used wrist devices. Based on the four registries, 32.7% (n = 36) out of 110 devices were validated, and 51.5% (n = 1407) out of 2731 patients used validated devices. Patients using validated devices tend to use more expensive devices than those using non-validated devices (P < 0.0001). Among Korean patients with hypertension undergoing HBPM, 97.0% of the patients used upper-arm devices and 51.5% of the patients used validated devices. Our results proposed the urgent need for patient education and public accessibility to validated devices for the better management of patients with hypertension. The validation status of HBPM devices was identified based on four registries: STRIDE BP, Medaval, the JSH, and dabl® Educational Trust. 51.5% (n = 1,407) out of 2,731 patients used validated devices and 32.7% (n = 36) out of 110 devices were validated. Patient education and public accessibility on validated devices are urgently needed. HBPM home blood pressure monitoring; JSH Japanese Society of Hypertension.
家庭血压监测(HBPM)的实施改善了高血压的诊断和治疗。当前的临床指南提倡使用经过验证的HBPM设备。然而,很少有研究考察过经过验证的HBPM设备的当前使用情况。我们旨在调查现实世界中高血压患者使用经过验证的HBPM设备的现状。本研究针对韩国高血压患者开展,使用了CareforMe®这款智能手机医疗应用程序,该程序允许患者记录其HBPM数据并与医生共享。基于四个注册机构(STRIDE BP、Medaval、日本高血压学会和dabl®教育信托基金)来确定HBPM设备的验证状态。从2022年1月到2024年8月,2731名患者输入了他们HBPM设备的型号。研究人群中56.4%(n = 1539)为男性,平均年龄为53.5±10.8岁。共识别出33个不同制造商的110种型号。97.0%(n = 2649)的患者使用上臂式设备,3.0%(n = 82)的患者使用腕式设备。根据这四个注册机构的情况,110种设备中有32.7%(n = 36)经过了验证,2731名患者中有51.5%(n = 1407)使用了经过验证的设备。使用经过验证的设备的患者往往比使用未经验证的设备的患者使用更昂贵的设备(P < 0.0001)。在接受HBPM的韩国高血压患者中,97.0%的患者使用上臂式设备,51.5%的患者使用经过验证的设备。我们的研究结果表明,迫切需要对患者进行教育,并使经过验证的设备能够为公众所用,以便更好地管理高血压患者。基于四个注册机构(STRIDE BP、Medaval、日本高血压学会和dabl®教育信托基金)来确定HBPM设备的验证状态。2731名患者中有51.5%(n = 1407)使用了经过验证的设备,110种设备中有32.7%(n = 36)经过了验证。迫切需要对患者进行关于经过验证的设备的教育,并使这些设备能够为公众所用。HBPM家庭血压监测;JSH日本高血压学会